Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Veeva Systems Inc Class A / Equity Bottom-Up

<ul><li>Veeva Systems has moved deeper into agentic AI for life sciences with its acquisition of Copli, an agentic medical, legal, and regulatory solutions provider that is now available as Veeva Falcon MLR.</li><li>The deal comes shortly after Veeva’s fiscal Q1 2027 earnings call, where management reported total quarterly revenue of $883 million and non-GAAP operating income of $395 million, while framing Falcon as a disruptive new layer of “agentic labor” across life sciences workflows.</li><li>Copli’s core appeal appears tied to one of pharma’s most persistent bottlenecks: MLR review, where promotional, medical, and regulatory content must be checked before reaching doctors and patients.</li></ul>

Veeva Systems has moved deeper into agentic AI for life sciences with its acquisition of Copli, an agentic medical, legal, and regulatory solutions provider that is now available as Veeva Falcon MLR.The deal comes shortly after Veeva’s fiscal Q1 2027 earnings call, where management reported total quarterly revenue of $883 million and non-GAAP operating income of $395 million, while framing Falcon as a disruptive new layer of “agentic labor” across life sciences workflows.Copli’s core appeal appears tied to one of pharma’s most persistent bottlenecks: MLR review, where promotional, medical, and regulatory content must be checked before reaching doctors and patients.

Veeva Systems' Latest Acquisition Pushes Agentic AI Deeper Into Pharma!